Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06917040

Enrollment

18404

Registered

2025-04-08

Start date

2021-02-01

Completion date

2022-04-01

Last updated

2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leishmaniasis, Cutaneous, Vector Borne Diseases

Keywords

Conflict, Internally displaced people, temporary shelter, spatial repellants

Brief summary

The aim of this study is to determine the efficacy of Mosquito Shield (spatial repellent) in reducing cutaneous leishmaniasis case incidence among internally displaced persons and sandfly density in temporary shelters and camp settings in Ar-Raqqa governorate, North-East Syria.

Interventions

DEVICESpatial repellant emanator

Spatial emanator with an active ingredient Transfluthrin (C15H12Cl2F4O2, 110mg, EPA registered number 432-1588).

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Masking description

Neither the deliverers of the intervention nor the outcome assessors are blinded to the group allocations

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

Known history of cutaneous leishmaniasis in camp Sleeping under same shelter type (all UNHCR tents / plastic sheets) Camp easily accessible by road Camps a minimum of 5km apart Adequate security levels

Exclusion criteria

Camps closer than 5km from a camp included in the study Camps with no previously recorded cases of cutaneous leishmaniasis Displaced communities living outside of defined camp settings

Design outcomes

Primary

Measure	Time frame	Description
Epidemiological outcome: cutaneous leishmaniasis incidence	11 or 9 months	Cutaneous leishmaniasis incidence per 1,000 will be estimated as the total number of cutaneous leishmaniasis episodes per 1,000 persons over the course of the trial. Two different incubation times or diagnostic cut-offs will be used: at 2 months post-intervention (from August 2021 to April 2022) and at 4 months post-intervention (from August 2021 to April 2022).
Entomological outcome: phlebotomine sandfly density	9 months	Phlebotomine sandfly density will be estimated monthly using Centers for Disease Control and Prevention light traps inside shelters.

Secondary

Measure	Time frame	Description
Intervention feasibility, acceptability and uptake	11 months	To measure community and household intervention acceptability and uptake, a questionnaire will be conducted post-intervention.

Countries

Syria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026